About Court Report: Each week we will report briefly on recently filed biotech and pharma cases.
Orexo AB et al. v. Actavis Elizabeth LLC et al.
1:16-cv-00397; filed May 27, 2016 in the District Court of Delaware
• Plaintiffs: Orexo AB; Orexo US, Inc.
• Defendants: Actavis Elizabeth LLC; Actavis Inc.
Infringement of U.S. Patent No. 9,259,421 ("Abuse-Resistant Pharmaceutical Composition for the Treatment of Opioid Dependencen" issued February 16, 2016) following a Paragraph IV certification as part of Actavis' amendment of its ANDA to manufacture a generic version of Orexo's Zubsolv® (buprenorphine hydrochloride and naloxone hydrochloride sublingual tablets, used the maintenance treatment of opioid dependence and for the induction of buprenorphine maintenance therapy in patients suffering from opioid dependence). View the complaint here.
Alvogen Pine Brook LLC v. Noven Pharmaceuticals, Inc. et al.
1:16-cv-00395; filed May 27, 2016 in the District Court of Delaware
• Plaintiff: Alvogen Pine Brook LLC
• Defendants: Noven Pharmaceuticals, Inc.; Hisamitsu Pharmaceutical Co., Inc.
Declaratory judgment of noninfringement of U.S. Patent Nos. 6,841,716 ("Patch," issued January 11, 2005) and 8,231,906 ("Transdermal Estrogen Device and Delivery," issued July 31, 2012) based on Alvogen's filing of an ANDA to manufacture a generic version of Noven's Minivelle® (estradiol transdermal system, used for the treatment of moderate to severe vasomotor symptoms due to menopause and for the prevention of postmenopausal osteoporosis). View the complaint here.
AbbVie Inc. v. Amneal Pharmaceuticals, LLC et al.
1:16-cv-00398; filed May 27, 2016 in the District Court of Delaware
• Plaintiff: AbbVie Inc.
• Defendants: Amneal Pharmaceuticals, LLC; Amneal Pharmaceuticals of New York, LLC
Infringement of U.S. Patent Nos. 7,148,359 ("Polymorph of a Pharmaceutical," issued December 12, 2006) and 7,364,752 ("Solid Dispersion Pharmaceutical Formulations," issued April 29, 2008) following a Paragraph IV certification as part of Amneal's filing of an ANDA to manufacture a generic version of AbbVie's Norvir® (ritonavir, used to treat human immunodeficiency virus (HIV) infection). View the complaint here.